Kidney Disease Recommendations Advise SGLT2 Inhibitors for All Patients
Updated guidelines for managing chronic kidney disease (CKD) now recommend that all patients with type 2 diabetes use sodium-glucose cotransporter-2 (SGLT2) inhibitors, according to a synopsis published in Annals of Internal Medicine.
Updated guidelines for managing chronic kidney disease (CKD) now recommend that all patients with type 2 diabetes use sodium-glucose cotransporter-2 (SGLT2) inhibitors, according to a synopsis published in Annals of Internal Medicine.
